Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

and in the US manufacturers of branded drugs have become adept at constructing patent defences to prevent competition. The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

For the study, investigators pitted the HER2-targeted antibody-drug conjugate against Eli Lilly ... cancer following prior treatment with a trastuzumab (Herceptin)-based regimen.

Number of Medicare claims for trastuzumab originator (Herceptin) and 5 biosimilars, by month, 2019–20 Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases ...